Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD8+ T cell states in human cancer: insights from single-cell analysis
Anne M. van der Leun, Daniela S. Thommen, Ton N. Schumacher
Nature reviews. Cancer (2020) Vol. 20, Iss. 4, pp. 218-232
Open Access | Times Cited: 1130

Showing 26-50 of 1130 citing articles:

Cancer associated-fibroblast-derived exosomes in cancer progression
Chao Li, Adilson Fonseca Teixeira, Hong‐Jian Zhu, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 216
Promises and challenges of adoptive T-cell therapies for solid tumours
Matteo Morotti, Ashwag Albukhari, Abdulkhaliq Alsaadi, et al.
British Journal of Cancer (2021) Vol. 124, Iss. 11, pp. 1759-1776
Open Access | Times Cited: 201
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
Lena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 199
Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing
Cornelius Kürten, Aditi Kulkarni, Anthony R. Cillo, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 192
Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma
Assaf Magen, Pauline Hamon, Nathalie Fiaschi, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1389-1399
Closed Access | Times Cited: 190
Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity
Jenna L. Collier, Sarah A. Weiss, Kristen E. Pauken, et al.
Nature Immunology (2021) Vol. 22, Iss. 7, pp. 809-819
Open Access | Times Cited: 175
Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy
Tobias Hoch, Daniel Schulz, Nils Eling, et al.
Science Immunology (2022) Vol. 7, Iss. 70
Open Access | Times Cited: 175
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
N. de Vries, Joris van de Haar, Vivien Veninga, et al.
Nature (2023) Vol. 613, Iss. 7945, pp. 743-750
Open Access | Times Cited: 175
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade
Baolin Liu, Yuanyuan Zhang, Dongfang Wang, et al.
Nature Cancer (2022) Vol. 3, Iss. 9, pp. 1123-1136
Closed Access | Times Cited: 173
CD8+ T cells in the cancer-immunity cycle
Josephine R. Giles, Anna-Maria Globig, Susan M. Kaech, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2231-2253
Open Access | Times Cited: 168
Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies
Daniel Reichart, Eric L. Lindberg, Henrike Maatz, et al.
Science (2022) Vol. 377, Iss. 6606
Open Access | Times Cited: 164
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
Fernanda G. Herrera, Catherine Ronet, Maria Ochoa de Olza, et al.
Cancer Discovery (2021) Vol. 12, Iss. 1, pp. 108-133
Open Access | Times Cited: 158
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
Thomas U. Marron, Maria Isabel Fiel, Pauline Hamon, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 3, pp. 219-229
Open Access | Times Cited: 155
Ovarian cancer mutational processes drive site-specific immune evasion
Ignacio Vázquez-Garćıa, Florian Uhlitz, Nicholas Ceglia, et al.
Nature (2022) Vol. 612, Iss. 7941, pp. 778-786
Open Access | Times Cited: 155
Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials
Hao Zhang, Xinghai Yue, Zhe Chen, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 153
Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers
Alicia Cristina Peña-Romero, Esteban Orenes‐Piñero
Cancers (2022) Vol. 14, Iss. 7, pp. 1681-1681
Open Access | Times Cited: 149
Mechanisms of drug resistance in HCC
Alexandra D. Ladd, Sergio Duarte, İlyas Şahin, et al.
Hepatology (2023)
Closed Access | Times Cited: 149
T cell factor 1: A master regulator of the T cell response in disease
Giulia Escobar, Davide Mangani, Ana C. Anderson
Science Immunology (2020) Vol. 5, Iss. 53
Open Access | Times Cited: 147
Contribution of resident and circulating precursors to tumor-infiltrating CD8 + T cell populations in lung cancer
Paul Gueguen, Christina Metoikidou, Thomas Dupic, et al.
Science Immunology (2021) Vol. 6, Iss. 55
Open Access | Times Cited: 140
Emerging concepts in PD-1 checkpoint biology
Kristen E. Pauken, James A. Torchia, Apoorvi Chaudhri, et al.
Seminars in Immunology (2021) Vol. 52, pp. 101480-101480
Open Access | Times Cited: 134
A Biomimetic Aggregation‐Induced Emission Photosensitizer with Antigen‐Presenting and Hitchhiking Function for Lipid Droplet Targeted Photodynamic Immunotherapy
Xiuli Xu, Guanjun Deng, Zhihong Sun, et al.
Advanced Materials (2021) Vol. 33, Iss. 33
Closed Access | Times Cited: 128
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
Victoria S. Pelly, Agrin Moeini, Lisanne M. Roelofsen, et al.
Cancer Discovery (2021) Vol. 11, Iss. 10, pp. 2602-2619
Open Access | Times Cited: 126
‘Stem-like’ precursors are the fount to sustain persistent CD8+ T cell responses
Dietmar Zehn, Robert Thimme, Enrico Lugli, et al.
Nature Immunology (2022) Vol. 23, Iss. 6, pp. 836-847
Open Access | Times Cited: 123
Uncovering the mode of action of engineered T cells in patient cancer organoids
Johanna F. Dekkers, María Alieva, Astrid Cleven, et al.
Nature Biotechnology (2022) Vol. 41, Iss. 1, pp. 60-69
Open Access | Times Cited: 121
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy
Jii Bum Lee, Hye Ryun Kim, Sang‐Jun Ha
Immune Network (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 119

Scroll to top